ProtoKinetix, Incorporated

Equities

PKTX

US7437221002

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:52:04 31/05/2024 BST			5-day change	1st Jan Change
0.0142 ^USD	+3.27%		+2.90%	-25.26%

05-15	ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-29	ProtoKinetix, Incorporated announced a financing transaction	CI

Protokinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2020

March 05, 2021 at 07:12 pm

ProtoKinetix, Incorporated announced earnings results for the full year ended December 31, 2020. For the full year, the company announced net loss was USD 7.644 million compared to USD 4.197 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.02 a year ago.

Latest news about ProtoKinetix, Incorporated

ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
ProtoKinetix, Incorporated announced a financing transaction	03-28	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.11 million in funding	12-25	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/10/23	CI
ProtoKinetix, Incorporated announced that it has received $0.03 million in funding	28/08/23	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/07/23	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	24/05/23	CI
ProtoKinetix, Incorporated announced that it has received $0.324 million in funding	24/05/23	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023	02/05/23	CI
ProtoKinetix, Incorporated Auditor Raises 'Going Concern' Doubt	16/03/23	CI
ProtoKinetix, Incorporated announced that it has received $0.04 million in funding	22/01/23	CI
ProtoKinetix, Incorporated announced a financing transaction	29/12/22	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.037 million in funding	29/12/22	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.063 million in funding	08/12/22	CI
ProtoKinetix, Incorporated announced a financing transaction	07/12/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	31/10/22	CI
ProtoKinetix, Incorporated announced that it has received funding	13/10/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	29/07/22	CI
ProtoKinetix, Incorporated Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants	20/07/22	CI
ProtoKinetix, Incorporated announced a financing transaction	10/07/22	CI
ProtoKinetix, Incorporated announced that it expects to receive $0.2 million in funding	10/07/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
ProtoKinetix, Incorporated announced that it has received $0.05 million in funding	17/03/22	CI
ProtoKinetix, Incorporated Reports Earnings Results for the Full Year Ended December 31, 2021	10/03/22	CI

Chart ProtoKinetix, Incorporated

Duration

Period

More charts

Company Profile

ProtoKinetix, Incorporated is a research and development stage biotechnology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins. The Companyâs anti-aging glycopeptide is for ophthalmology, dermatology, transplant support and biomanufacturing. The commercial applications for AAGPs include various health care solutions. In a clinical setting, AAGP is showing its ability to protect cells from inflammation, repair and replace damaged cells and improve cell survivability over time. The Company has not developed a commercially viable product and has not generated any revenue.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PROTOKINETIX, INCORPORATED	-25.26%	5.01M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research